Related Experiment Video
Updated: Apr 21, 2026
Ex Vivo Expansion of Hematopoietic Stem Cells from Human Umbilical Cord Blood-derived CD34+ Cells Using Valproic Acid
Published on: April 11, 2019
[Autologous peripheral blood CD34+ stem cells transplanted into 100 patients with advanced cirrhosis]
Yutong Yao1, Lanyun Luo, Hua Xue
1School of Medicine, UESTC and Sichuan Provincial People's Hospital, Chengdu 610072, China.
Insights
Autologous peripheral blood CD34+ stem cell transplantation offers a safe and effective treatment for advanced cirrhosis. This therapy improves liver function, histology, and quality of life, addressing donor shortages.
Area of Science:
- Hepatology
- Regenerative Medicine
- Stem Cell Therapy
Background:
- Advanced cirrhosis presents a significant clinical challenge, often limited by donor organ availability.
- Current treatments for advanced cirrhosis are insufficient, necessitating novel therapeutic approaches.
Purpose of the Study:
- To evaluate the efficacy and safety of autologous peripheral blood CD34+ stem cell transplantation in patients with advanced cirrhosis.
- To assess the impact of stem cell transplantation on liver function, histology, and patient quality of life.
Main Methods:
- 100 patients with advanced cirrhosis received autologous peripheral blood CD34+ stem cell transplantation.
- Outcomes were assessed at 6 and 12 months, measuring liver biosynthesis function, liver elasticity, and pathological/morphological changes.
- Complications were monitored throughout the follow-up period.
Main Results:
- 1-year cumulative survival rate was 100%.
- Significant improvements observed in liver biosynthesis function, liver elasticity, and Knodell scores (P < 0.05).
- Reduction in ascites and manageable complications were noted.
Conclusions:
- Autologous CD34+ stem cell transplantation is a safe and effective treatment for advanced cirrhosis.
- The procedure demonstrates a high cost-benefit ratio by improving liver function, histology, and quality of life.
- This approach offers a promising alternative for patients with advanced cirrhosis, mitigating donor organ limitations.
Objective:
To investigate whether transplantation of autologous peripheral blood CD34+ stem cells is a viable approach for treating patients with advanced cirrhosis,which is currently hindered by a shortage in liver donors.
Methods:
A total of 100 patients with advanced cirrhosis and who had failed to respond to conservative therapy were recruited for transplantation of autologous peripheral blood CD34+ stem cells.The success of transplantation was investigated 6-and 12-months later by measuring markers of liver biosynthesis function (coagulation,albumin level,indocyanine green clearance,Child-Pugh score) and assessing pathological changes (Knodell score) and morphologic changes in the liver tissue.Complications were also recorded during follow-up.
Results:
The 1-year cumulative survival rate was 100%. Fifty-two patients with massive ascites showed gradual reduction and disappearance of the ascites.Four patients experienced upper gastrointestinal bleeding and three patients developed with hepatic encephalopathy (I-II degree) at 3 months post-transplantation.All patients showed significantly improved liver biosynthesis function,liver elasticity and Knodell score after transplantation (P less than 0.05).
Conclusion:
Autologous peripheral blood CD34+ stem cell transplantation is a safe and effective treatment for advanced cirrhosis,and has high cost-benefit since it improves liver function,liver histology,and quality of life.
Related Concept Videos
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...